RegWardenFDA facility compliance records
Facility

Koios Medical, Inc.

1 recall(s) on record — most severe on record: Class II.

Activity by year

FDA actions on record by year2019: 1 recalls; 2021: 1 inspections201720181201920201202120222023202420252026
  • Recalls (1)
  • Inspections (1)

Devices registered here (2)

  • Computer-Assisted Diagnostic Software For Lesions Suspicious For Cancer
    Product code POK (opens in a new tab) · Class II · Radiology · 21 CFR 892.2060
  • Automated Radiological Image Processing Software
    Product code QIH (opens in a new tab) · Class II · Radiology · 21 CFR 892.2050

Recalls & enforcement

  • Class IITerminated2019-12-31
    Affected software product versions were found during internal audit to have been marketed for sale without sufficient documentation pertaining to certain required quality procedures.

FDA inspections (1)

  • VAI2021-05-13
    Voluntary Action Indicated · Compliance: Devices; Postmarket Assurance: Devices · citations posted

Source: U.S. FDA Inspections Dashboard (opens in a new tab) (device inspection classifications, 2016–present). Data as of 2026-10-06. The dashboard profile can take several seconds to load.

Related

Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this facility record at FDA → (opens in a new tab)

Cite this record

RegWarden. “Koios Medical, Inc. (FEI 3010119782) — FDA facility record.” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/facility/3010119782-koios-medical-inc/

Not open yet

Alerts for Koios Medical, Inc.

Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.

Planned

Want a one-page facility brief?

A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.